SNY - First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential | Benzinga
Wednesday, Sanofi SA (NASDAQ:SNY) reported results from the Phase 2 study of oral rilzabrutinib in adult patients with uncontrolled moderate-to-severe asthma.
Two doses of rilzabrutinib, 800 mg daily and 1200 mg daily, were studied.
The data showed that treatment with oral rilzabrutinib at both high and low doses led to a numerical reduction in loss of asthma control (LOAC) events (the primary endpoint) and improvements in symptoms in adult patients with uncontrolled moderate-to-severe asthma.
These results were presented at the 2024 American Thoracic Society ...